Navigation Links
Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
Date:1/24/2011

fluoroquinolones), older age (over 65) and exposure to emerging hyper-virulent strains (BI/NAP1/027, 078, 001) of C. difficile. The increasing incidence of CDI, along with higher rates of both treatment failures and recurrences with current therapies have resulted in greater awareness and concern about CDI among medical professionals and public health officials. You may learn more about CDI at www.cdiinfo.org, a website of Optimer.

About FidaxomicinFidaxomicin is the first in a new class of antibiotics called macrocycles, which inhibit the bacterial enzyme RNA polymerase, resulting in the rapid killing of C. difficile. The narrow-spectrum profile of fidaxomicin eradicates C. difficile selectively with minimal disruption to the normal intestinal flora, while the alternative antibiotics used to treat CDI, metronidazole and vancomycin, have been shown to disrupt the gut flora. Fidaxomicin facilitates the return of normal physiological conditions in the colon which may be responsible for reducing CDI recurrence rates. Optimer has filed applications in the U.S. and the EU for marketing authorization for fidaxomicin for the treatment of CDI and reducing risk of recurrence when used for treatment of initial CDI.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin).  Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).  The Company has submitted an NDA to the FDA, and filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being deve
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Passport Health, one of the ... has launched FluFree.com, a website designed to promote, educate ... For 20 years, Passport Health has provided its clients ... launch of FluFree.com is designed to address the growing ... of people who actually chose to get vaccinated. ...
(Date:9/30/2014)... 2014   Acutus Medical, Inc. (ACM), ... 3D Cardiac Chamber Imaging and Dipole Density Mapping system ... sustain complex cardiac arrhythmias, including atrial fibrillation, announced it ... its imaging/mapping system as well as bring to market ... Medical to complete work on the AcQMap TM ...
(Date:9/30/2014)... , Sept. 30, 2014 Headquartered in ... is a diversified company comprised of several specialized partners ... technology and the proven expertise of its team of ... wellness. WholeHealth Products, line of more than 10 professional ... and its more than 8 retail consumer tests is ...
Breaking Medicine Technology:Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3WholeHealth Products Announces The Discovery Of The "Autism And Fragile X" Microwell And Rapid Diagnostic Test 2
... July 19 Nycomed US Inc. today announced the appointment ... assumes immediate responsibility for Nycomed US Inc., including manufacturing in Melville ... the three marketing and sales divisions Fougera, PharmaDerm and Savage Laboratories. ... Steve Andrzejewski ...
... NEW YORK , July 19 Reportlinker.com announces that a new market research ... , Global Pharma-biotech Alliance ... http://www.reportlinker.com/p0234517/Global-Pharma-biotech-Alliance-Analysis.html , ... This IBD provides an overview of the pharma-biotech alliance deals struck from 2008 to present. ...
Cached Medicine Technology:Steve Andrzejewski Joins Nycomed US Inc. 2Reportlinker Adds Global Pharma-biotech Alliance Analysis 2
(Date:9/30/2014)... A group of Americans is headed to a ... left unchecked, could create a catastrophic, global pandemic. No, it’s ... John Rogers, the Executive Director the Eugene Bell Foundation and ... disease most think mankind conquered long ago: tuberculosis. , “Tuberculosis, ... on the comeback in several countries - what’s especially disconcerting ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- Medicare should ... at high risk for the disease, a coalition of ... The coalition, which includes the Lung Cancer Alliance, the ... the American Cancer Society and the American Society of ... Monday to the U.S. Centers for Medicare & Medicaid ...
(Date:9/30/2014)... gene mutation that causes a rare premature aging disease ... the rapid, unstoppable cell division that makes cancer so ... and the U-M Health System recently discovered a protein ... which precious hematopoietic stem cells can,t regenerate and make ... prone to cancer and bone marrow failure. , ...
(Date:9/30/2014)... Healthpointe is proud to announce that ... and ankle reconstruction surgeries to assist patients with severe ... specializes in the diagnosis and treatment of sports medicine, ... also trained to perform advanced Foot and Ankle Reconstruction ... is also fluent in Spanish. , Reconstructive surgical procedures ...
(Date:9/30/2014)... September 30, 2014 Jiwa Law Corporation, a ... that it will now be offering free consultation for personal ... visit the law firm for the first time to meet ... be given the opportunity to understand what their rights are. ... with the client to explain to them what the law ...
Breaking Medicine News(10 mins):Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 3Health News:Jiwa Law Corporation Now Offers Personal Injury Consultation Without Any Charge 2
... Calif., April 22 DURECT,Corporation (Nasdaq: DRRX ... Executive Officer, will be presenting at the Morgan ... 2008 at 8:30 a.m. ET.,The conference is being ... (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ), A live ...
... Therapeutics,(Amex: CXM ) and its operating unit ... System will be featured on Science,Channel,s "Cool Stuff: ... will,feature InnerCool,s endovascular cooling during a 6-hour brain ... 25, 2008 at 8:00 p.m. (ET/PT). Please,visit ...
... prices have risen,sharply over the last 12 months, organic ... expected to continue in 2008, according to,the Organic Trade ... safer than conventional foods, they are also more expensive.,Because ... looking,to strike a balance between their desire to eat ...
... April 21, 2008 3M Health Care, a leader ... announces plans to introduce the 3M Rapid Detection Flu ... qualitative and objective electronic results in 15 minutes. , ... season, the Rapid Detection Flu Test quickly delivers objective ...
... GeneGo, Inc., the leading,provider of software and databases ... the Chinese University of Hong Kong,Pediatric department will ... drug targets for a large variety of diseases ... to license MetaCore, as well as,species-specific content for ...
... POUGHKEEPSIE, N.Y., April 22 Just in time ... ) is rolling,out a new line of high-end ... -- and the well-being of its customers., ... covers made of bamboo -- a renewable resource ...
Cached Medicine News:Health News:Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works' 2Health News:Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works' 3Health News:Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works' 4Health News:Eat Well, Save Money: BJ's Offers Everyday Low Prices on Top Quality Organic Groceries, Natural Foods Versus Supermarket Prices 2Health News:Eat Well, Save Money: BJ's Offers Everyday Low Prices on Top Quality Organic Groceries, Natural Foods Versus Supermarket Prices 3Health News:3M Health Care announces new 3M Rapid Detection Flu A+B test 2Health News:GeneGo's First Customer in Hong Kong; The Chinese University of Hong Kong 2Health News:Bragada(R) Luxury Mattress, Inc. Goes Green 2
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
... Seven digital models cover the range from ... liquid fluently. Volume lock design prevents inadvertent ... the horizontal grip. Whole pipette is autoclavable ... ejector is all polypropylene. Suitable for one-handed ...
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: